MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
GSK - Glaxosmithkline plc
$29.43
0.07(0.24%)8:00:01 PM 9/30/2022
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap59.9B
PE Ratio12.1
PEG Ratio3.1
P/B6.7
P/S (ttm)3.1
Earning Growth (QoQ)-31%
Revenue Growth (QoQ)
Short %0%
Held by Institutions %13%
1 Day Vol Adjusted Return0.1
1 Month Vol Adjusted Return-6.6
3 Month Vol Adjusted Return-20.5
6 Month Vol Adjusted Return-23.6
20 Days SMA Price ZScore-1.0
50 Days SMA Price ZScore-1.2
12 -26 Days PPO-5.3
1 Month Average Short Volume Ratio35.1
1 Day Volume Change ZScore-0.3
1 Month Daily Vol1.4
Related Topics
leak data

Related Topics

Peers

Stock news

    09/29/2022GSK
    GSK (GSK) Stock Moves -0.34%: What You Should Know

    GSK (GSK) closed at $29.36 in the latest trading session, marking a -0.34% move from the prior day.

    09/27/2022GSK
    At GSK, women now hold both the CFO and CEO roles

    Burberry CFO Julie Brown was named the next finance chief at GSK, joining CEO Emma Walmsley.

    09/26/2022GSK
    GSK Taps Burberry Executive As CFO

    Pharmaceutical firm GSK hired the finance chief of British luxury fashion group Burberry to lead its finances after the recent spinoff of its consumer-health business.

    09/26/2022GSK
    Burberry Finance Chief Joins GSK As First Woman CFO

    GSK plc (NYSE: GSK) has appointed Julie Brown as its first-ever female chief financial officer to succeed Iain Mackay. Mackay, 60, will retire next year after serving as GSK's finance chief for nearly four years. Julie will join GSK in April 2023 and will work with Iain to transition responsibilities, taking responsibility as CFO and as an Executive Director of GSK on 1 May 2023. Ms. Brown currently serves as Chief Operating and Financial Officer at the luxury fashion brand Burberry Group plc (O

    09/26/2022GSK
    Unilever CEO Alan Jope To Retire Next Year

    British consumer goods giant Unilever PLC (NYSE: UL) Chief Executive Officer Alan Jope intends to retire in 2023 end. The decision comes after the CEO came under severe criticism over a failed takeover bid of drugmaker GSK Plc's (NYSE: GSK) consumer health unit worth £50 billion ($53 billion), Bloomberg reported. GSK rejected Unilever's bid and ended up spinning off its consumer healthcare business into an independently-traded public company, named Haleon. The company reported an underlying EPS

    09/25/2022GSK
    This Infection-Fighting Biotech Is Recovering Nicely

    After a deal with GlaxoSmithKline, the small-cap antibiotic developer Spero Therapeutics should get a shot as an options play.

    09/24/2022GSK
    UPDATE 1-GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News

    British drugmaker GSK plc has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday. GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019, the report added. On Friday, Burberry announced that its finance chief Julie Brown will step down in April 2023 after more than five years in the role.

    09/23/2022GSK
    Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

    The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

    09/23/2022GSK
    Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

    Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.